Patents by Inventor Jan Weiler
Jan Weiler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11578130Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.Type: GrantFiled: December 5, 2018Date of Patent: February 14, 2023Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
-
Publication number: 20230026049Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.Type: ApplicationFiled: April 28, 2022Publication date: January 26, 2023Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
-
Publication number: 20220411796Abstract: Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.Type: ApplicationFiled: July 20, 2022Publication date: December 29, 2022Inventors: Manuela Polydoro Ofengeim, Jan Weiler
-
Patent number: 11473083Abstract: Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.Type: GrantFiled: December 19, 2016Date of Patent: October 18, 2022Assignee: NOVARTIS AGInventors: Manuela Polydoro Ofengeim, Jan Weiler
-
Patent number: 11261444Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preeclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.Type: GrantFiled: January 21, 2020Date of Patent: March 1, 2022Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Huesken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
-
Patent number: 11066667Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: GrantFiled: February 6, 2019Date of Patent: July 20, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Publication number: 20210180053Abstract: A manufacturing process of RNA having a length of about 20-200 bases with improved performance, by using in vitro transcription in combination with other methodologies that may increase yield and quality.Type: ApplicationFiled: October 31, 2018Publication date: June 17, 2021Inventors: Michael BEVERLY, Caitlin Jeanette HAGEN, Olga SLACK, Jan WEILER
-
Patent number: 11008570Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: GrantFiled: January 16, 2019Date of Patent: May 18, 2021Assignee: Novartis AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Publication number: 20200190517Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.Type: ApplicationFiled: January 21, 2020Publication date: June 18, 2020Inventors: Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dleter Heusken, Stuart Milstein, JR., Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
-
Patent number: 10538765Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic imflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.Type: GrantFiled: December 7, 2017Date of Patent: January 21, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Huesken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
-
Patent number: 10519446Abstract: The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3? end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. In some embodiments, the 3? end of both the sense and anti-sense strand further comprise, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3? end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker.Type: GrantFiled: September 30, 2014Date of Patent: December 31, 2019Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu, Meghan Holdorf
-
Publication number: 20190390196Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: ApplicationFiled: January 16, 2019Publication date: December 26, 2019Applicant: Novartis AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Publication number: 20190323008Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.Type: ApplicationFiled: June 24, 2019Publication date: October 24, 2019Inventors: Jinyun Chen, Kalyani Gampa, Dieter Huesken, Frank Stegmeier, Mark Stump, Chandra Vargeese, Jan Weiler, Wenlai Zhou
-
Publication number: 20190263914Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.Type: ApplicationFiled: December 5, 2018Publication date: August 29, 2019Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
-
Publication number: 20190233817Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: ApplicationFiled: February 6, 2019Publication date: August 1, 2019Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Patent number: 10329563Abstract: The present disclosure relates to methods of treating heat stock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.Type: GrantFiled: May 5, 2017Date of Patent: June 25, 2019Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Jinyun Chen, Kalyani Gampa, Dieter Huesken, Frank Stegmeier, Mark Stump, Chandra Vargeese, Jan Weiler, Wenlai Zhou
-
Patent number: 10287354Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.Type: GrantFiled: December 19, 2014Date of Patent: May 14, 2019Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
-
Patent number: 10240153Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: GrantFiled: January 11, 2017Date of Patent: March 26, 2019Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Patent number: 10227588Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: GrantFiled: October 1, 2014Date of Patent: March 12, 2019Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Publication number: 20180282728Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.Type: ApplicationFiled: June 13, 2018Publication date: October 4, 2018Inventors: Brian Richard Bettencourt, David Anton Bumcrot, Dieter Huesken, Satyanarayana Kuchimanchi, Stuart Milstein, Michael Ray Schlabach, JR., Frank Peter Stegmeier, Markus Warmuth, Jan Weiler